Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Pilot Study of Plasma Cell-Free DNA Fragmentomics in Gallbladder Cancer.

JHEP reports : innovation in hepatology·2026
Same author

SurvivEHR: a competing risks, time-to-event foundation model for multiple long-term conditions from primary care electronic health records.

NPJ digital medicine·2026
Same author

Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes (BSPED) and the Association of British Clinical Diabetologists (ABCD).

Diabetic medicine : a journal of the British Diabetic Association·2026
Same author

Leveraging the PEDSnet clinical research network and electronic health record data to enhance efficiency of trial enrollment for a rare pediatric rheumatic disease.

Pediatric rheumatology online journal·2026
Same author

The Risk of Suicide Attempts After Head Injury: A Matched UK Population-Based Cohort Study.

Neurology·2025
Same author

Identifying Predictors of Recurrent Pilonidal Disease in Adolescents and Young Adults: A Secondary Analysis of a Randomized Controlled Trial.

The Journal of surgical research·2025

Related Experiment Video

Updated: Jun 13, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

TNFalpha gene delivery therapy for solid tumors.

Jonathan Hernandez1, Jennifer Cooper, Nitin Babel

  • 1Department of Surgery, University of South Florida, College of Medicine, The Tampa General Hospital, Center for Digestive Disorders, 1 Tampa General Circle, Tampa, Florida 33601, USA.

Expert Opinion on Biological Therapy
|April 17, 2010
PubMed
Summary
This summary is machine-generated.

A novel gene delivery system enhances tumor necrosis factor-alpha (TNFalpha) production directly within tumors, offering a promising adjunctive cancer therapy with reduced systemic toxicity. Ongoing trials will clarify its role in treating solid tumors.

More Related Videos

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

A Rabbit Model of Durable Transgene Expression in Jugular Vein to Common Carotid Artery Interposition Grafts
13:58

A Rabbit Model of Durable Transgene Expression in Jugular Vein to Common Carotid Artery Interposition Grafts

Published on: September 10, 2018

Related Experiment Videos

Last Updated: Jun 13, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

A Rabbit Model of Durable Transgene Expression in Jugular Vein to Common Carotid Artery Interposition Grafts
13:58

A Rabbit Model of Durable Transgene Expression in Jugular Vein to Common Carotid Artery Interposition Grafts

Published on: September 10, 2018

Area of Science:

  • Oncolytic Virotherapy
  • Gene Therapy
  • Cancer Treatment

Background:

  • Multimodality cancer therapy often causes significant host toxicity, potentially leading to treatment failures.
  • Novel adjunctive treatments are needed to reduce systemic exposure while enhancing standard cancer therapies.
  • Targeted delivery systems hold promise for improved cancer treatment outcomes.

Purpose of the Study:

  • To review a novel gene delivery system for intratumoral tumor necrosis factor-alpha (TNFalpha) production.
  • To evaluate the potential of this system as an adjunctive cancer therapy.
  • To discuss product characteristics, mechanisms, efficacy, safety, and tolerability.

Main Methods:

  • Utilized a replication-deficient adenoviral vector for gene delivery.
  • Administered the vector intratumorally, followed by external beam radiation for activation.
  • Achieved high levels of localized TNFalpha synthesis and secretion within tumors.

Main Results:

  • The gene delivery system demonstrated the ability to generate substantial intratumoral TNFalpha.
  • Systemic exposure to TNFalpha was significantly limited.
  • The review emphasizes product characteristics, mechanism of action, clinical efficacy, safety, and tolerability.

Conclusions:

  • The TNFalpha gene delivery system shows potential as an adjunctive treatment for solid tumors.
  • It may improve local tumor control and increase resectability rates.
  • Further data from ongoing randomized trials are crucial to define its definitive role in cancer therapy.